Clinical Effect Of Roxadustat Combined With Erythropoietin In The Treatment Of Renal Anemia In Patients Undergoing Hemodialysis

Objective:To observe the clinical efficacy and safety of roxadustat and the combination of roxadustat and erythropoietin(EPO)in the treatment of renal anemia in patients undergoing hemodialysis.Methods:A total of 90 patients undergoing hemodialysis with renal anemia admitted to the Department of Nephrology of the Affiliated Hospital of Guizhou Medical University,People’s Hospital of Guizhou Province and the Baiyun Hospital Affiliated to Guizhou Medical University from May 2020 to December 2021 were collected and divided into 3 groups: EPO group(group A,n=30),roxadustat group(group B,n=30),roxadustat combined with EPO group(group C,n=30).The hemoglobin(Hb)was respectirely tested before treatment and 4,8 and 12 weeks after treatment.The levels of serum iron,triglyceride and C-reactive protein(CRP)were tested before treatment and 12 weeks after treatment.The adverse reactions were recorded.Results:There were no significant differences in baseline indexes among three groups(P>0.05).Group B and group C led to a higher mean hemoglobin level at week24 than group A[(104.93±15.012)g/L vs.(98.30±13.33)g/L,P=0.019;(104.43±10.49)g/L vs.(98.30±13.33)g/L,P=0.029].Treatment for 12 weeks,total iron binding capacity was higher in group B and group C compared with group A(P<0.05),and no significant differences were found in ferritin,serum iron and transferrin saturation among three groups(P>0.05).Group B and group C led to lower triglyceride level and total cholesterol level at week12 than group A.In patients with C-reactive protein > 5 mg/L,Group B and group C led to a higher hemoglobin level than group A(P<0.05).No significant differences were found in Hb,serum iron,triglyceride and other indicators between group B and group C(P>0.05).During the treatment,no significant difference was found in the incidence of adverse reactions among three groups(P>0.05),and no MACE+events occurred in any patient.Conclusions:In the treatment of renal anemia in patients undergoing hemodialysis,roxadustat and roxadustat combined with EPO are both effective,and the efficacy of roxadustat may be better than that of EPO;Roxadustat or roxadustat combined with EPO is well tolerated in the treatment of renal anemia.